Will the U.S. repeal the future Medicaid spending cuts by the end of 2026?

Will the percentage of uninsured patients in U.S. hospitals exceed 25% by September 30, 2026?

This market resolves to Yes if the average percentage of uninsured patients reported by major U.S. hospitals exceeds 25% by the end of Q3 2026, as indicated in their publicly available earnings reports or official statements.

This market resolves to Yes if, by August 30, 2026, Troy Jackson (Democratic nominee for the 2026 midterms in Maine) publicly announces a detailed and actionable statewide plan for implementing Medicare for All. This announcement must include specific policy details and key legislative or executive steps, and must be reported by a reputable news outlet or Jackson's official campaign channels. Ambiguous statements or generalized support for Medicare for All will not count.

This market resolves to Yes if Tempus AI successfully finalizes its $1.7 billion acquisition of cancer-tech firm Personalis by October 15, 2026. Successful finalization requires an official announcement from Tempus AI, Personalis, or relevant regulators confirming the deal's closure. If the acquisition is announced as abandoned or not completed by the resolution date, this market will resolve to No.

This market resolves to Yes if the CDC publicly states or announces that the Cyclospora outbreak linked to Taco Bell lettuce is officially over by August 15, 2026. The declaration must be made on the CDC's official platforms or in an official press release. Otherwise, the market resolves to No.

This market resolves to Yes if the WHO's Europe Regional Office publicly announces the finalization and publication of its new digital health strategy by August 31, 2026. The resolution will be based on official and verifiable announcements from the WHO Regional Office for Europe or relevant trusted media sources. If no announcement is made by this date, the market resolves to No.

This market resolves to Yes if the U.S. Food and Drug Administration (FDA) announces formal approval of the first regenerative injection therapy for osteo-arthritis, as described in recent research news, by August 31, 2026. Any official FDA announcement, press release, or public database update confirming approval will determine the outcome. If no such approval is granted by the close date, the market resolves to No.